GlaxoSmithKline (GSK) will begin Phase III development to evaluate the efficacy and safety of retosiban, an investigational oxytocin antagonist. Retosiban is being developed as a potential treatment to improve neonatal outcomes of babies born to women in spontaneous preterm labor by prolonging the time to delivery.

Retosiban is thought to work by blocking the effects of oxytocin, a hormone produced by the body during labor, in order to stop preterm labor and thereby increase gestational age at birth.

Source: GlaxoSmithKline